Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

/PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...

Related Keywords

Philadelphia ,Pennsylvania ,United States ,John Hohneker ,Steven Kelly ,Shveta Dighe ,Chidozie Ugwumba ,Prnewswire Carisma Therapeutics Inc ,Carisma Therapeutics Inc ,Moderna Tx Inc ,Nasdaq ,Company Annual Report On Form ,Drug Administration ,Sesen Bio Inc ,Exchange Commission ,Board Of Directors The Company ,While The Company ,Chief Executive Officer ,Pipeline Updates ,Upcoming Milestones ,Investigational New Drug ,Moderna Collaboration ,Full Year ,Cash Equivalents ,Sesen Bio ,Private Securities Litigation Reform Act ,Annual Report ,Convertible Preferred Stock ,Stockholder Equity ,Carisma Therapeutics ,